Top

International Journal of Clinical Oncology

Published in:

01-12-2011 | Original Article

Serum human telomerase reverse transcriptase: a novel biomarker for breast cancer diagnosis

Authors: Mahendar Porika, Radhika Tippani, Sekhar R. Bollam, Sree Divya Panuganti, Christopher Thamidala, Sadanandam Abbagani

Published in: International Journal of Clinical Oncology | Issue 6/2011

Abstract

Background

Telomerase is a ribonucleoprotein complex composed mainly of a reverse transcriptase catalytic subunit, telomerase reverse transcriptase (hTERT). Expression of hTERT confers telomerase activity, indicating that hTERT is the rate-limiting component of human telomerase. The aim of the present study was to investigate the diagnostic implications of hTERT in the serum of breast cancer patients.

Methods

The study was conducted on 159 breast cancer patients and 41 healthy volunteers as controls. The evaluation of hTERT, cancer antigen 15.3 and carcinoembryonic antigen were performed by enzyme-linked immunosorbent assay, and analysed for their correlation with the patient’s clinicopathological features.

Results

27 of 52 (51.9%) patients with stage I breast cancer, 31 of 40 (77.5%) with stage II and 30 of 34 (88.2%) patients with stage III exhibited elevated hTERT levels. Serum hTERT levels showed significantly higher mean values in patients with breast cancer than healthy individuals. The sensitivity and specificity of hTERT in cancer diagnosis was 68.9 and 83.3%, respectively, which is significantly higher than conventional markers. The expression of serum hTERT was significantly correlated with telomerase activity in breast cancer tissues. Pretreatment serum hTERT levels showed a significant correlation with clinical stage, while correlation with nodal status and tumor size were marginal and no correlation was found with family history and age.

Conclusion

Serum hTERT is useful for diagnosing and assessing the clinical stage of breast cancer and is superior to conventional markers. Therefore, serum hTERT could have a potential application as a novel biomarker for breast cancer diagnosis.

Umi MAH, Louise R, Radka S et al (2008) A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 18:1105–1118CrossRef

Yeole BB, Kumar AVR, Kurkure A et al (2004) Population based survival from cancers of breast, cervix and ovary in women in Mumbai, India. Asian Pac J Cancer Prev 5:308–315PubMed

Chatterjee SK, Zetter BR (2005) Cancer biomarkers: knowing the present and predicting the future. Future Oncol 1:37–50PubMedCrossRef

Mahendar P, Nagulu M, Uday Kiran V et al (2010) Evaluation of tumor markers in southern Indian breast cancer patients. Asian Pac J Cancer Prev 11:157–159

Duffy MJ (2006) Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52:345–351PubMedCrossRef

Blackburn EH (1994) Telomeres: no end in sight. Cell 77:621–623PubMedCrossRef

Watson JD (1972) Origin of concatemeric T7 DNA. Nat New Biol 239:197–201PubMedCrossRef

Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33:787–791PubMedCrossRef

Mahendar P, Uday Kiran V, Radhika K et al (2009) Detection of telomerase activity in different cancer tissues: early detection. Curr Trends Biotechnol Pharmacy 3:105–110

10.

Cairney CJ, Keth WN (2008) Telomerase redefined: Integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie 90:13–23PubMedCrossRef

11.

Mokbel K (2000) The role of telomerase in breast cancer. Eur J Surg Oncol 26:509–514PubMedCrossRef

12.

Wu A, Ichihashi M, Ueda M (1999) Correlation of the expression of human telomerase subunits with telomerase activity in normal skin and skin tumors. Cancer 86:2038–2044PubMedCrossRef

13.

Bachand F, Triki I, Autexier C (2001) Human telomerase RNA–protein interactions. Nucleic Acids Res 29:3385–3393PubMedCrossRef

14.

Meng L, Rong FW, Chun LZ et al (2007) Noninvasive imaging of human telomerase reverse transcriptase (hTERT) messenger RNA with 99mTC-radiolabeled antisense probes in malignant tumors. J Nucl Med 48:2028–2036CrossRef

15.

Novakovic S, Hocevar M, Zgajnar J et al (2004) Detection of telomerase RNA in the plasma of patients with breast cancer, malignant melanoma or thyroid cancer. Oncol Rep 11:245–252PubMed

16.

Liliana T, Enrica R, Salvatore P et al (2008) Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res 14:7444–7451CrossRef

17.

Masutomi K, Shuichi K, Mami Y et al (2002) Identification of serum anti-human telomerase reverse transcriptase (hTERT) auto-antibodies during progression to hepatocellular carcinoma. Oncogene 21:5946–5950PubMedCrossRef

18.

Miura N, Maruyama S, Oyama K et al (2007) Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma. Oncology 72:45–51PubMedCrossRef

19.

Mezzasoma L, Antognelli C, Del Buono C et al (2010) Expression and biological-clinical significance of hTR, hTERT and CKS2 in washing fluids of patients with bladder cancer. BMC Urol 10:1–10CrossRef

20.

Hiyama E, Hiyama K (2003) Telomerase as tumor marker. Cancer Lett 194:221–233PubMedCrossRef

21.

Gabriele S (2009) Telomerase, mitochondria and oxidative stress. Exp Gerontol 44:485–492CrossRef

22.

Hiyama E, Hiyama K, Tatsumoto N et al (1996) Telomerase activity in human intestine. Int J Oncol 9:453–458PubMed

23.

Ali ASM, Chopra R, Robertson J et al (2000) Detection of hTERT protein by flow cytometry. Leukemia 14:2176–2181PubMedCrossRef

24.

XU D, Gruber A, Peterson C et al (1998) Telomerase activity and the expression of telomerase components in acute myelogenous leukaemia. Br J Haematol 102:1367–1375PubMedCrossRef

25.

Jong HS, Park YI, Kim S et al (1999) Up-regulation of human telomerase catalytic subunit during gastric carcinogenesis. Cancer 15:559–565CrossRef

26.

Toshikuni N, Nouso K, Higashi T et al (2000) Expression of telomerase-associated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma. Br J Cancer 82:833–837PubMedCrossRef

27.

Kirkpatrick KL, Clark G, Ghilchick M et al (2003) hTERT mRNA expression correlates with telomerase activity in human breast cancer. Eur J Surg Oncol 29:321–326PubMedCrossRef

28.

Ramirez JL, Sarries C, de Castro PL et al (2003) Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett 193:207–216PubMedCrossRef

29.

Kim NW, Piatyszek MA, Prowse KR et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 226:2011–2015CrossRef

30.

Poole JC, Andrews LG, Tollefsbol TO (2001) Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 269:1–12PubMedCrossRef

31.

Orlando C, Gelmini S, Selli C et al (2001) Telomerase in urological malignancy. J Urol 166:666–673PubMedCrossRef

32.

Zhang Y, He DM (2002) Effect of antisense hTERT mRNA oligodeoxynucleotide on telomerase activity of leukemic cells. Cell Biol Int 26:427–431PubMedCrossRef

33.

Peter JFS, Roderick HJB, Thomas GS et al (2004) Elevated hTERT mRNA levels: a potential determinant of bronchial squamous cell carcinoma (in situ). Int J Cancer 109:412–417CrossRef

34.

Francisco D, Salvador L, Eduardo GG et al (2001) Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test to monitor disease in cancer patients. Lab Invest 81:767–769CrossRef

35.

Kirkpatrick KL, Ogunkolade W, Elkak AE et al (2003) hTERT expression in human breast cancer and non-cancerous breast tissue: correlation with tumour stage and c-Myc expression. Breast Cancer Res Treat 77:277–284PubMedCrossRef

36.

Salhab M, Jiang WG, Newbold RF et al (2008) The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome. Breast Cancer Res Treat 109:35–46PubMedCrossRef

37.

Li YR, Wu JM, Wang L et al (2005) Human telomerase reverse transcriptase expression and its clinical significance in laryngeal squamous cell carcinoma. Acta Otolaryngol 125:409–414PubMedCrossRef

38.

Miura N, Kanamori Y, Takahashi M et al (2007) A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies. Oncol Rep 17:541–548PubMed

39.

Miura N, Maeda Y, Kanbe T et al (2005) Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res 11:3205–3209PubMedCrossRef

40.

Miura N, Osaki Y, Nagashima M et al (2010) A novel biomarker TERT mRNA is applicable for early detection of hepatoma. BMC Gastroenterol 10:1–12CrossRef

41.

Mahendar P, Radhika T, Anwar M et al (2011) Evaluation of serum human telomerase reverse transcriptase as a novel marker for cervical cancer. Int J Biol Markers 26:22–26. doi:10.5301/JBM.2011.6352

42.

Chen XQ, Bonnefoi H, Pelte MF et al (2000) Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 6:3823–3826PubMed

43.

He DM, Zhang H (2004) Telomerase activity and hTERT mRNA expression in acute leukemia. Chin J Cancer Res 16:289–291CrossRef

44.

Chun L, Ming-Yao W, Ying-Rui L et al (2003) Correlation between expression of human telomerase subunits and telomerase activity in esophageal squamous cell carcinoma. World J Gastroenterol 9:2395–2399

Title: Serum human telomerase reverse transcriptase: a novel biomarker for breast cancer diagnosis
Authors: Mahendar Porika
Radhika Tippani
Sekhar R. Bollam
Sree Divya Panuganti
Christopher Thamidala
Sadanandam Abbagani
Publication date: 01-12-2011
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 6/2011
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-011-0230-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2011

An early event of EGFR mutation in pleomorphic carcinoma of the lung

Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer

Clinical utility and prospective comparison of ultrasonography and computed tomography imaging in staging of neck metastases in head and neck squamous cell cancer in an Indian setup

A case of primary alveolar soft part sarcoma of the uterine cervix and a review of the literature

Surrogacy of tumor response and progression-free survival for overall survival in metastatic breast cancer resistant to both anthracyclines and taxanes

Lung cancer: atypical brain metastases mimicking neurocysticercosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer